Dianthus Therapeutics (NASDAQ:DNTH) EVP Ryan Savitz Sells 8,224 Shares

Key Points

• EVP Ryan Savitz sold 8,224 shares of Dianthus on April 9 at an average price of $89.84 for about $738,844, reducing his stake by 50%; the transaction was executed under a pre-arranged Rule 10b5-1 plan and follows a March 31 sale of 114,367 shares (~$9.49M).
• Shares recently traded near $89.77 (one-year high $92.27) with 50-day/200-day moving averages of $66.73/$49.34 and a market capitalization of roughly $3.99 billion, while the company remains unprofitable after missing quarterly EPS estimates.
• Wall Street sentiment is largely positive, with a consensus "Buy" rating and an average price target of $115.55 as multiple firms raised targets or reiterated buy/outperform ratings.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) EVP Ryan Savitz sold 8,224 shares of Dianthus Therapeutics stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the completion of the transaction, the executive vice president directly owned 8,224 shares of the company's stock, valued at approximately $738,844.16. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Savitz also recently made the following trade(s):

• On Tuesday, March 31st, Ryan Savitz sold 114,367 shares of Dianthus Therapeutics stock. The shares were sold at an average price of $83.00, for a total value of $9,492,461.00.

Dianthus Therapeutics Price Performance

Shares of Dianthus Therapeutics stock traded down $1.89 on Friday, hitting $89.77. 481,113 shares of the company's stock traded hands, compared to its average volume of 1,047,549. The company has a fifty day moving average of $66.73 and a two-hundred day moving average of $49.34. Dianthus Therapeutics, Inc. has a one year low of $15.25 and a one year high of $92.27. The company has a market capitalization of $3.99 billion, a price-to-earnings ratio of -21.90 and a beta of 1.22.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.97) by ($0.46). The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.40 million. Dianthus Therapeutics had a negative return on equity of 38.85% and a negative net margin of 7,973.33%. Equities research analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Wall Street Analysts Forecast Growth

DNTH has been the topic of a number of research reports. Wedbush boosted their target price on shares of Dianthus Therapeutics from $55.00 to $80.00 and gave the company an "outperform" rating in a research report on Tuesday, March 10th. Stifel Nicolaus set a $120.00 price target on shares of Dianthus Therapeutics in a report on Monday, March 9th. TD Cowen reaffirmed a "buy" rating on shares of Dianthus Therapeutics in a research note on Monday, March 9th. Truist Financial upped their price objective on shares of Dianthus Therapeutics from $63.00 to $110.00 and gave the company a "buy" rating in a report on Monday, March 9th. Finally, Jefferies Financial Group set a $98.00 price objective on shares of Dianthus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Dianthus Therapeutics presently has a consensus rating of "Buy" and an average price target of $115.55.

Hedge Funds Weigh In On Dianthus Therapeutics

A number of large investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd acquired a new stake in Dianthus Therapeutics in the 4th quarter valued at $43,000. Seven Fleet Capital Management LP acquired a new position in Dianthus Therapeutics during the fourth quarter worth $604,000. Invesco Ltd. raised its holdings in Dianthus Therapeutics by 125.9% during the fourth quarter. Invesco Ltd. now owns 101,489 shares of the company's stock worth $4,182,000 after buying an additional 56,560 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Dianthus Therapeutics in the fourth quarter valued at $550,000. Finally, Voloridge Investment Management LLC lifted its stake in shares of Dianthus Therapeutics by 80.5% in the fourth quarter. Voloridge Investment Management LLC now owns 39,480 shares of the company's stock valued at $1,627,000 after buying an additional 17,612 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.